{"id":"tp-44343","type":"article-newspaper","title":"Novartis Sales Rise 4% as U.S. Patent or Exclusivity Expirations Are Estimated for 2031","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/44343","datePublished":"2026-10-30T06:31:14.000Z","dateModified":"2026-10-30T06:31:14.000Z","language":"en","abstract":"Kisqali and Kesimpta grew, while remibrutinib reduced relapse rates versus teriflunomide in two Phase III trials.","section":"Business","references":[{"title":"third-quarter results","url":"https://www.tokenpost.com/news/business/41571"}]}